Get started
Author

Karl-Maria Schumacher

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
2011 · Robert Pirker, Jose R Pereira, et al. · The Lancet Oncology · 576
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study
2010 · Ulrich Gatzemeier, Joachim von Pawel, et al. · The Lancet Oncology · 118
Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp).
2021 · Xiuning Le, Luis G. Paz-Ares, et al. · Journal of Clinical Oncology · 40
Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.
2021 · Jyoti D. Patel, Xiuning Le, et al. · Journal of Clinical Oncology · 15
PERSPECTIVE: Tepotinib + cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).
2021 · Tanios S. Bekaii-Saab, Eric Van Cutsem, et al. · Journal of Clinical Oncology · 4
Intracranial Activity of Tepotinib in Patients (pts) With MET exon 14 (METex14) Skipping NSCLC Enrolled in VISION
2022 · C.M. Bestvina, J.D. Patel, et al. · International Journal of Radiation Oncology*Biology*Physics · 3
Tepotinib in Patients with Advanced NSCLC with MET Amplification (METamp)
2022 · X. Le, R. O'Hara, et al. · International Journal of Radiation Oncology*Biology*Physics · 1
Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
PDF
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
PDF
Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
PDF
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
PDF
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
PDF
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
PDF
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
PDF
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
PDF
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
2023 · Xiuning Le, Hiroshi Sakai, et al.
Works count: 29
Citation count: 757
H-index: 4
I10-index: 4
Year
Topic
Type